Search

A joint position paper on molecular tumor boards (MTBs) in Taiwan has been published by the Taiwan Oncology Society (TOS) and the Taiwan Society of Pathology (TSP). The paper, formulated by 20 experts from TOS and TSP, aims to raise awareness of MTBs among healthcare professionals, policymakers, and the public. The paper proposes key recommendations for MTB discussions, including the incorporation of diverse molecular analyses, involvement of multidisciplinary participants, prioritization of cases with unique clinical needs, and the use of comprehensive patient data. The primary goal of this initiative is to promote the advancement of precision oncology in Taiwan. [Extracted from the article]

HanxBio has published a research paper titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the journal Scientific Reports. The paper describes the preclinical evaluation of Narazaciclib (HX301) for the treatment of acute myeloid leukemia (AML). The researchers conducted comprehensive pharmacology characterization of HX301 using various preclinical experimental AML models, demonstrating its strong anti-leukemia activity and potential mechanisms of action. The study also investigated the pharmacodynamics and pharmacokinetics of HX301, providing valuable information for clinical dosage selection. The results of this study will guide the clinical development strategies for HX301 in the treatment of AML. [Extracted from the article]

A consensus paper from University Hospital in Charleroi, Belgium discusses the role of the cerebellum in human gait and its assessment and therapy. The cerebellum is critical for postural control and mapping sensory information into motor commands. Ataxia of stance/gait is a common symptom in cerebellar disorders and can lead to falls. The understanding of the cerebellar contribution to gait control can improve the management of cerebellar ataxias and potentially use gait parameters as biomarkers in future clinical trials. [Extracted from the article]

A recent study conducted by the Zena and Michael A. Wiener Cardiovascular Institute in New York City aimed to improve the understanding and treatment of acute decompensated heart failure (ADHF). ADHF is a common reason for hospitalizations and urgent care, but current therapies are limited. The study proposed standardized definitions for ADHF and highlighted important considerations for clinical trials of drugs and devices in this area. The research was supported by Bayer AG and Abiomed and involved collaboration between clinical investigators, clinicians, patients, government representatives, payors, and industry collaborators. The study's findings have been published in JACC Heart Failure. [Extracted from the article]

A recent study conducted at Flinders Medical Centre in Adelaide, Australia, examined the effects of increased water intake on patients with idiopathic calcium stones. The study found that patients who increased their water intake to at least 2 liters per day had a reduced recurrence rate of kidney stones compared to those who did not increase their water intake. The findings suggest that kidney stone patients should aim for a fluid intake of at least 2.5 liters per day to prevent stone recurrence. This information can be valuable for clinical practice and guideline recommendations. [Extracted from the article]

A recent study conducted by the Mayo Clinic and published in Critical Care Medicine addresses the issue of norepinephrine formulation labeling and its implications for clinical practice and research. The study involved a multinational and multidisciplinary task force of critical care experts from the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. The task force concluded that there are significant differences in norepinephrine formulations, which can have implications for patient safety, clinical care, and research. They recommended the use of a uniform norepinephrine-base formulation for global use and provided guidance for appropriate stakeholders. [Extracted from the article]

Researchers from the University of Calabria in Italy have utilized a machine learning platform called MySLR to identify case-control studies on mutations of the apolipoprotein E (ApoE) gene in Italian Alzheimer's Disease patients. The platform analyzed 164 scientific publications and identified 92 relevant papers, with 65.22% focusing on Italian Alzheimer's Disease patients and 5.4% discussing mutations in the ApoE gene. The study concluded that the machine learning platform was effective in identifying case-control studies on ApoE gene mutations in Italy. [Extracted from the article]